Drug intelligence / Profile preview

ATB224

Development stage: Preclinical
Lead developer: AltiBio

Overview

ATB224 is a drug candidate developed by AltiBio, a biopharmaceutical company founded by former Raptor Pharmaceuticals executives. It is being developed for undisclosed rare diseases and has shown positive preclinical proof of concept studies. The development of ATB224 is supported by a Series A Preferred Stock financing closed in September 2018, intended to advance early-stage programs, including further proof of concept studies, formulation development, and clinical trials.

Beyond the preview

Go deeper on ATB224.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATB224.

Explore the full profile